Discounted Cash Flow (DCF) Analysis Levered

Mirum Pharmaceuticals, Inc. (MIRM)

$26.02

-0.11 (-0.42%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ---------
Revenue (%)
Operating Cash Flow ---------
Operating Cash Flow (%)
Capital Expenditure ---------
Capital Expenditure (%)
Free Cash Flow ---------

Weighted Average Cost Of Capital

Share price $ 26.02
Beta 1.317
Diluted Shares Outstanding 33.98
Cost of Debt
Tax Rate 4.51
After-tax Cost of Debt 697.37%
Risk-Free Rate
Market Risk Premium
Cost of Equity 9.925
Total Debt 2.19
Total Equity 884.22
Total Capital 886.41
Debt Weighting 0.25
Equity Weighting 99.75
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ---------
Operating Cash Flow ---------
Capital Expenditure ---------
Free Cash Flow ---------
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 11.62
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -25.82
Equity Value -
Shares Outstanding 33.98
Equity Value Per Share -